Estradiol/Norethindrone Acetate + Placebo for Elagolix + Elagolix + Placebo for E2/NETA
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Endometriosis
Conditions
Endometriosis
Trial Timeline
Jul 7, 2017 → Dec 6, 2023
NCT ID
NCT03213457About Estradiol/Norethindrone Acetate + Placebo for Elagolix + Elagolix + Placebo for E2/NETA
Estradiol/Norethindrone Acetate + Placebo for Elagolix + Elagolix + Placebo for E2/NETA is a phase 3 stage product being developed by AbbVie for Endometriosis. The current trial status is completed. This product is registered under clinical trial identifier NCT03213457. Target conditions include Endometriosis.
What happened to similar drugs?
1 of 18 similar drugs in Endometriosis were approved
Approved (1) Terminated (3) Active (14)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03213457 | Phase 3 | Completed |
Competing Products
20 competing products in Endometriosis